News
ASRT
0.8273
+2.83%
0.0228
Sidoti Remains a Hold on Assertio Therapeutics (ASRT)
TipRanks · 4d ago
Weekly Report: what happened at ASRT last week (0106-0110)?
Weekly Report · 01/13 11:10
Weekly Report: what happened at ASRT last week (1230-0103)?
Weekly Report · 01/06 11:17
ASSERTIO HOLDINGS, INC. REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 01/03 21:30
Press Release: Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dow Jones · 01/03 21:30
Weekly Report: what happened at ASRT last week (1223-1227)?
Weekly Report · 12/30/2024 11:11
Weekly Report: what happened at ASRT last week (1216-1220)?
Weekly Report · 12/23/2024 11:17
Assertio Therapeutics Announces Leadership Changes and Board Addition
TipRanks · 12/17/2024 22:28
ASSERTIO HOLDINGS, INC. APPOINTS MARK REISENAUER TO ITS BOARD OF DIRECTORS
Reuters · 12/17/2024 13:30
Press Release: Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
Dow Jones · 12/17/2024 13:30
Positive Clinical Results and Market Potential Drive Buy Rating for Assertio Therapeutics
TipRanks · 12/16/2024 18:45
Assertio Holdings Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
Dow Jones · 12/16/2024 12:21
HC Wainwright & Co. Reiterates Buy on Assertio Holdings, Maintains $4 Price Target
Benzinga · 12/16/2024 12:11
Promising Buy Rating for Assertio Therapeutics Backed by Positive ROLVEDON Trial Results and Market Potential
TipRanks · 12/16/2024 11:36
Weekly Report: what happened at ASRT last week (1209-1213)?
Weekly Report · 12/16/2024 11:19
Executive reshuffles: JPM, QCOM, DVN and LTC
Seeking Alpha · 12/14/2024 20:54
Assertio Holdings announces results of Rolvedon injection study
TipRanks · 12/13/2024 13:05
Assertio Announces Results Of A Clinical Trial Investigating The Utility Of Rolvedon Injection When Dosed The Same Day Of Chemotherapy For Patients With Early Stage Breast Cancer
Benzinga · 12/13/2024 13:03
ASSERTIO ANNOUNCES RESULTS OF ROLVEDON® (EFLAPEGRASTIM-XNST) INJECTION SAME-DAY DOSING CLINICAL STUDY
Reuters · 12/13/2024 13:00
ASSERTIO HOLDINGS INC - ROLVEDON SHOWS 1.8 DAYS TO NEUTROPHIL COUNT RECOVERY
Reuters · 12/13/2024 13:00
More
Webull provides a variety of real-time ASRT stock news. You can receive the latest news about Assertio Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About ASRT
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).